The objective of this study was to determine the incidence of drug resistance among isolates of Acinetobacter baumannii from our Burn Intensive Care Unit (BICU), the rate of clinical cure, and the mortality rate. We undertook a retrospective review of all cases of infection from 
Infection in the critically ill burned patient remains one of the most important contributors to morbidity and mortality. Despite advances in prevention, prophylaxis, and seemingly adequate therapeutic regimens, serious life-threatening infections still plague the seriously burned patient during the critical phases of recovery. [1] [2] [3] [4] [5] The most frequently encountered infections, including ventilator-associated pneumonia (VAP), catheter-related bloodstream infection, urinary tract infection, and wound infections, are generally caused by known nosocomial pathogens, with predictable drug sensitivities. 2 However, time has shown that the microbial environment of a critical care unit is a dynamic and complex system, and the most frequent pathogens are likely to change over time, as well as their respective drug sensitivities. 6 Acinetobacter baumannii has emerged as a new threat to the burn patient population. Serious infections from this previously benign organism are reported with increasing frequency, and national infection surveillance programs now recognize it as a major component of nosocomial pathogens. 6 -11 Of additional concern is the changing drug sensitivities, which now display increasing drug resistance to conventional therapeutic agents. After encountering multiple cases of resistant Acenitobacter infection in the burn inten-sive care unit (BICU) of our institution, we decided to review our experience dealing with this organism. The purpose of this study was to determine the incidence of multidrug resistance (MDR) among A. baumannii isolates from our institution, the cure rate of A. baumannii infection in critically ill burned patients, and the mortality associated with it. We defined A. baumannii as being MDR when displaying resistance to imipenem and one or more other drugs to which the organism is historically know to be sensitive. We also attempted to define the efficacy of the specific drug regimens used.
MATERIALS AND METHODS
We performed a retrospective review of all cases of A. baumannii infection from the BICU of our institution between January 2004 and November 2005. All documented infections during the study period were reviewed. Microbiological reports, electronic notes from the BICU attending, as well as laboratory data were reviewed.
For each patient, the primary site of infection was defined as the first positive culture for A. baumannii. The time between BICU admission and the first positive culture and the time between culture acquisition and initiation of adequate treatment was determined. Because this study was retrospective, we could not define strict clinical criteria that could be followed by the treating physician to determine clinical cure and end of treatment. In this context, we concluded that when an attending note documented that culturedirected treatment against A. baumannii was to be stopped, the patient had sufficient clinical and/or microbiological evidence that cure was achieved. The duration of treatment was recorded as well as the specific agent chosen and the route of administration. All-cause in-ICU and in-hospital mortality were recorded. We defined recurrent infection as a new positive culture at the initial site after a successful full course of culture-directed antibiotic treatment. Analysis was performed using descriptive statistics including means and standard deviations. Comparisons for individual variables were performed using z-test for proportions ( 
RESULTS
We identified 35 patients that had a positive culture with A. baumannii in the BICU during the study period. Of these, we excluded 5 patients that harbored the organism on a single culture from the tip of a removed central venous catheter, and no treatment was deemed necessary in all cases. Two of those 5 patients died during the study period from noninfectious causes (1 cardiac failure, 1 multiple organ failure [MOF] without sepsis). The remaining 30 patients were included for analysis. The group consisted of 24 men (80%), with a mean age of 43 years (range, 17-76 years, Ϯ14.5 years). The mean TBSA burned was 43% (range, 9 -75%, Ϯ19%). The mean BICU length of stay (LOS) was 49 days (range, 5-118 days, Ϯ30 days) and mean hospital LOS was 63 days (6 -140 days, Ϯ37 days). The patients developed their first infection with A. baumannii after a mean of 16 days (range, 5-73 days, Ϯ14 days) in the BICU.
The initial site of infection was from bronchoalveolar lavage (BAL) in 21 patients (70%), from blood in 6 patients (20%), from central venous catheter tip in 2 patients (7%), and from urine in 1 patient (3%). A BAL was considered positive with greater than 10 4 colony-forming units (CFU)/ml, a blood culture when any growth was reported, a central venous catheter tip infection when greater than 15 CFU were present, and a urinary tract infection when greater than 10 5 CFU/ml of the organism was observed. The initial positive culture was polymicrobial in 17 cases of the 21 BAL (81%), with gram-positive organisms in 9 cases (6 oxacillin-sensitive Staphylococcus aureus, 2 methicillin-resistant Staphylococcus aureus and 1 Streptococcus pneumoniae), and gram-negative organisms in 8 cases (3 Pseudomonas aeruginos a, 3 Enterobacteriacea, 1 Proteus mirabilis, and 1 Klebsiella pneumoniae). Patients had a positive culture with A. baumannii at more than one site during their BICU stay in 20 cases (67%).
The isolates displayed resistance to minocycline in 37% of cases, to amikacin in 63% of cases, to tobramycin in 80% of cases, and to imipenem in 87% of cases. Defining MDR as resistance to imipenem and one or more other drug tested, we found an incidence of 87% of MDR among the isolates of A. baumannii recovered. No organism displayed resistance to colistin. Patients were treated with colistin in 20 cases (67%), receiving the intravenous form in 9 cases (45%) and the nebulized form in 11 cases (55%). The intravenous dose was 2 mg/kg every 12 hours, adjusted to 2 mg/kg every 24 hours for creatinine clearance of 10 to 50 ml/min and to 2 mg/kg every 36 hours for creatinine clearance of less than 10 ml/min. Patients being dialyzed received 1 mg/kg after dialysis.
We did not perform routine monitoring of the drug level. In the nebulized colistin group, the dosage used was 75 mg nebulized every 12 hours. The most frequent adverse events related to colistin are renal failure for the intravenous form and bronchorrea for the nebulized form. These events were not uniformly measured and, with the small number of patients in this study, it is difficult to draw conclusions regarding adverse events with colistin use. In nine cases, a combination of drugs were used based on drug sensitivities. Each of these nine cases had colistin and a second antibiotic (either minocycline, doxycyline, or amikacin). The remaining patients received amikacin alone in 8 cases (27%) and imipenem alone in 2 cases (7%). In 21 cases (70%), clinical cure was achieved during their BICU stay, with a mean duration of treatment of 16 days (range, 4 -30 days, Ϯ7 days). Only three cases developed recurrent infection after a successful initial course of treatment.
A total of 10 patients (33%) died during their BICU stay, 1 from gastrointestinal bleeding and 9 from active infection creating septic shock and MOF, for an infection-related mortality of 30%. In the patients infected with the imipenem-sensitive organism, one died (25%) and, in the MDR group, we found nine deaths, one from the gastrointestinal bleeding and eight from sepsis and MOF (31%).We found no significant differences between survivors and nonsurvivors in TBSA, time in BICU before development of infection, site of initial, infection, pattern of resistance (MDR or non-MDR), duration of treatment, or time between obtaining the culture and initiation of treatment. However, patients in the nonsurvivor group were significantly older (49 vs 40 years, respectively, P ϭ .025; Table 1 ). Multivariate regression did not reveal any independent predictors of survival, likely as a result of the small sample size. One of the nonsurvivors deserves particular mention. The patient was a 41-year-old man who developed progressive cardiac failure in a septic context, with synchronous arythmias but without evidence of myocardial ischemia. His workup included transoesophageal echocardiography on two occasions, use of pulmonary artery catheter, and conventional tools for coronary artery disease and myocardial ischemia evaluation (electrocardiogram, cardiac enzymes). They revealed decreased cardiac output, global hypokinesia, small pericardial effusion, and no evidence of ischemia. The patient eventually died, and autopsy revealed the presence of a 95% stenosis of the left anterior descending artery and purulent bacterial pericarditis caused by a gram-negative organism, most likely A. baumannii because the patient was growing the organism repeatedly in his cultures. Unfortunately, no culture was sent by the medical examiner at the time of autopsy. 12 This demonstrates the potential ability of this very resistant organism to migrate to atypical clinical sites of infection.
DISCUSSION
Acinetobacter strains are nonfermenting aerobic gramnegative coccobacillary organisms, usually demonstrating diploid formations or chains. They can be found in soil and water as free-living saprophytes and are occasionally found colonizing skin, aero-digestive mucosa, and the gastrointestinal tract. 13 Twenty-one DNA homology groups have been described based on DNA-DNA relationships within the Acinetobacter genus.
14 Different species of the genus are predominant in different environments, and A. baumannii is the species most frequently encountered in the hospital setting.
In the medical environment, the organism has been cultured from multiple sources in either surveillance programs or investigation of epidemic outbreaks. A. baumannii has been found on inanimate surfaces such as pillows, bed mattresses, curtains, door handles, and computer keyboards, even after cleaning with antiseptic solutions. [15] [16] [17] [18] It seems that the organism also prefers warm and moist environments, and it has been found on respiratory equipment, humidifiers, and sinks. 19 However, the capacity of Acinetobacter to survive on dry surfaces and to sustain dessication has also been demonstrated. 17, 18 Health care workers in contact with infected patients also have been shown to harbor the organisms on their hands and play a potential role in epidemic outbreaks through contamination of the environment and other patients. 16 Numerous studies have attempted to identify potential risk factors predisposing to the nosocomial acquisition of A. baumannii. Most were retrospective studies and used univariate analysis. The most frequently identified risk factors were malignancy, 20 APACHE II score, 20, 21 mechanical ventilation, 20, [22] [23] [24] [25] prior use of antibiotics, and placement of intravascular catheters 20,22-24 among others. By multivariate analysis, severity of illness, burns, mechanical ventilation, male sex, duration of ICU stay before infection, and use of third-generation cephalosporins were found to be independent risk factors for acquisition of A. baumannii infection. 20, 23, 24 In the present study, we unfortunately did not obtain data from all patients admitted to the BICU that would have allowed us to identify risk factors for the acquisition of the infection.
In early in vitro studies, the vast majority of Acinetobacter isolates were sensitive to ampicillin, cephalosporins, and aminoglycosides. 26 -28 Clearly, however, the resistance patterns have changed with the increased prevalence of infection and antibiotic use. In 1995, Lyytikainen et al 15 described their experience during the course of 4 years (1989 -1993) and found the resistance to imipenem increased from 1.5% to 7% and resistance to tobramycin increased from 5% to 12%. 15 Others have reported imipenem resistance in the range of 11% to 24% from more recently published data (2003) (2004) (2005) . 20 In the report by Hanberger in 1999 analyzing microbiological data from 5 European countries, Acinetobacter species were found to have the highest increase in resistance to antibiotics of all the gram-negative bacilli studied. 11 The report from Paul and colleagues from Israel found an increase in resistance to imipenem from 10% to 34% between 1997 and 2002. 9 In our series, A. baumannii isolates displayed a much higher incidence of resistance to imipenem (87%). The explanation may lie in the frequent use of imipenem or piperacillin as the empiric regimen used for suspected gram-negative coverage in our institution. Weinbren and colleagues suggested that the use of carbapenems in their BICU could be responsible for an increase in drug resistance, as they observed a significant increase (four to eightfold) in the minimal inhibitory concentration of imipenem for their Acinetobacter isolates under a policy of using meropenem for suspected gram-negative infections. 29 In contrast, LeFloch et al 30 described using a systematic antibiotic regimen composed of imipenem and tobramycin for suspected gram-negative infections. They found the incidence of Acinetobacter and Pseudomonas had decreased, but incidence of Enterobacter and Klebsiella as well as resistance to ticarcillin had increased.
With increasing drug resistance, clinicians are faced with difficult decisions regarding therapeutic choices. Colistin has been reintroduced as a treatment option, and a few published reports have described its use in cases of Acinetobacter and Pseudomonas infections. [31] [32] [33] [34] [35] [36] [37] [38] However, the use of colistin in a nebulized form has been published more scarcely. 33, 39 Interestingly, we did not encounter resistance to colistin in any of our isolates. We used a daily dose of 4 mg/kg of colistin intravenously divided in two doses for the patients with normal renal function. The recommended dose is 2 to 5 mg/kg daily, divided in two doses, depending on the severity of the infection. We did not monitor for the drug levels, and the dose was adjusted to renal clearance in case of renal failure. The nebulized form was reserved for patients with isolated VAP and no evidence of bloodstream infection. In the burn population, published experience with colistin and evaluation of the pharmacokinetics is still lacking. Future development of our own experience will have to include research on the kinetics of the drug in our burn population and tissue levels measurement in wounds, blood and alveoli.
Newer agents have been recently introduced, including tigecycline, a glycylcycline, which shows in vitro and in vivo activity against A. baumannii. 40 This agent is presently approved by the Food and Drug Administration for skin and skin-structures infections as well as complicated intra-abdominal infections. More research is required to address the efficacy of this new agent in cases of nosocomial A. baumannii infection in ICUs. Nevertheless, it appears to be a promising option at this time.
The infection related mortality in our group was 30%, and we found similar rates in the recent literature. Bang et al 41 found a 30% mortality in their 1998 report. Sengupta et al 42 found a 38% mortality rate in their unit in 2001. Wisplinghoff et al 43 found a 31% total mortality rate in their group in 1999, but the infection related mortality rate was lower (7%). This lower rate of mortality may be related to the fact that all isolates in the study by Wisplinghoff were susceptible to imipenem, whereas most of our isolates were resistant to imipenem. However, our small number of patients prevents us from identifying a significant difference in outcome between patients infected with the resistant and the susceptible strains. Two recent reports looked at the morbidity related to A. baumannii infection. Wilson et al 44 found that patients in their burn unit who developed a A. baumannii infection had a significantly higher mean hospital cost of $98,575 per patient when compared with matched controls. Wong et al 45 found A. baumannii infection to be an independent risk factor for increased length of stay in the BICU in their retrospective analysis published in 2002.
All our cases of infection with A. baumannii were nosocomial. This pathogen has become endemic to the trauma intensive care unit of our institution, which shares a geographically adjacent space with the burn ICU. In the last 3 years, this pathogen has become encountered more frequently in the BICU as well as in the surgical ICU, and the study was aimed at acquiring further knowledge of the infection. Preventive measures have been put in place by the infection control department of our institution consisting of contact precautions for known cases, isolation of cases, education of healthcare workers to preventive measures, distribution of personal-size hand disinfectant to workers, and monitoring of new cases. Environmental measures also have been applied with installation of plastic curtains that can be cleaned with bactericidal solutions. Despite these measures implemented before and throughout the study period, the number of new cases found monthly has not declined and only stayed stable. A. baumannii is now the most frequently cultured gram-negative pathogen found both in the trauma ICU and the BICU of our institution. Further work is required in identifying strategies to reduce the number of new cases and to decontaminate our environment. A prospective observational study is presently underway in our institution to help identify the incidence of MDR organisms carriage in the population served by our resources. All trauma and burned patients admitted have stool samples collected upon admission and in the following weeks when hospitalized. We aim at finding the incidence of carriage and hopefully acquire data that could be correlated to clinical infections during their hospitalization.
CONCLUSION
We found an important number of A. baumannii infections in our BICU population during the 2-year duration of our study. The isolates showed resistance to imipenem in 87% of cases but not to colistin. Mortality in this group of patient was high (30%). With increasing numbers of cases and increased resistance to antibiotics, it is now even more important to investigate and improve the prevention and treatment of this life-threatening organism.
